Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.

DISC-3405 may serve as an adjunctive therapy, not a replacement, for hydroxyurea or interferon, according to Naseema Gangat, MBBS.

DISC-0974 may have utility as monotherapy or in combination with other JAK inhibitors, according to Naseema Gangat, MBBS.

At SOHO 2026, Jasmine Zain, MD, discussed communicating the FDA’s boxed warning for secondary malignancies post–CAR T-cell therapy to patients.

Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.